Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody

DRUG3 trials

Conditions

Bladder CancerNon-Small Cell Lung CancerNon-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Phase 2

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

CompletedNCT01846416

Genentech, Inc.Non-Small Cell Lung Cancer

Start: 2013-05-30End: 2017-12-18Updated: 2019-01-08

Phase 3

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

CompletedNCT02302807

Hoffmann-La RocheBladder Cancer

Start: 2015-01-13End: 2018-11-08Updated: 2019-08-01

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

CompletedNCT02409342

Hoffmann-La RocheNon-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

Start: 2015-07-20End: 2022-03-08Updated: 2023-03-15

Journal of Clinical Oncology2025-05-28

Atezolizumab monotherapy as first-line treatment for non-small cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a cost-effectiveness analysis in the USA

BMJ Open2024-11-01

Potential synergistic effects of cranial radiotherapy and atezolizumab in non-small cell lung cancer: an analysis of individual patient data from seven prospective trials.

2024-01-293 citations

606 IMpower110: Tertiary lymphoid structures (TLS) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with first-line atezolizumab or chemotherapy

Regular and Young Investigator Award Abstracts2023-10-313 citations

Immune Checkpoints are Important Therapeutic Targets in Cancer Immunotherapy

Cancer Science & Research2021-12-30

329 Early blood cell count test (BCT) for survival prediction for non-small cell lung cancer patients treated with atezolizumab: integrated analysis of 4 multicenter clinical trials

Regular and Young Investigator Award Abstracts2021-11-011 citations

Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.

2021-04-2378 citations

Multiorgan Immune-Related Adverse Events Linked to Survival Gain

Oncology Times2020-11-11

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

New England Journal of Medicine2020-09-301619 citations

IMpower110: Clinical safety in a phase III study of atezolizumab (atezo) monotherapy (mono) vs platinum-based chemotherapy (chemo) in first-line non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2020-05-2014 citations

Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.

Journal of Clinical Oncology2020-05-204 citations

O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC

Oral Presentations2020-04-018 citations

Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC).

Journal of Clinical Oncology2020-02-19

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

Cancer Chemotherapy and Pharmacology2019-09-2186 citations

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.

2018-11-01119 citations

Biological features and clinical outcomes in atezolizumab (atezo)-treated patients (pts) with metastatic urothelial cancer (mUC) of the upper vs lower urinary tract (UTUC vs LTUC)

Annals of Oncology2018-10-016 citations

Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial

BMC Cancer2018-07-312 citations

Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.

Journal of Clinical Oncology2018-05-2057 citations

Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210.

Journal of Clinical Oncology2018-05-2036 citations

A Network Meta-Analysis of the Pd(L)-1 Inhibitors in the Salvage Treatment of Urothelial Bladder Cancer

Immunotherapy2018-03-2212 citations

6 more papers not shown

Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody

Sponsors

Conditions

Phase 2

Phase 3

Related Papers